Sangamo and Pfizer Announce Updated Results of Investigational Hemophilia A Gene Therapy

The following is an excerpt from a press release from Sangamo. Read the press release in its entirety here. Sangamo Therapeutics Inc., a genomic medicine company, and Pfizer Inc. announced updated results from the Phase 1/2 Alta study evaluating investigational SB-525 gene therapy for severe hemophilia A.The data showed that SB-525 was generally well-tolerated and […]